United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Trevi Therapeutics reports promising results for Oral Nalbuphine in human abuse potential study Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced positive oral nalbuphine results from its human abuse potential (HAP)… byPallavi MadhirajuDecember 4, 2024